Cardiovascular disease (CVD) is the number one cause of death wordwide1. The cause of CVD is atherosclerosis. Cardiovascular risk does not correlate with clinical symptoms until considerable atherosclerotic disease progression. Consequently, early accurate CVD risk assessment is part of an established clinical strategy of primary prevention. A number of guidelines have been established for the prevention, diagnosis, evaluation and management of CVD. The goal being the reduction of cardiac events such as acute heart attack (myocardial infarction, MI) and stroke. CVD risk assessment is therefore a key aspect of clinical care for all individuals between the age of 40-79.
Clinical CV risk factors include hypertension, diabetes mellitus, chronic kidney disease, obesity, cigarette smoking and family history. The most important biomarkers for CV risk determination are lipids including total cholesterol, triglycerides, LDL and HDL cholesterol. Early epidemiological studies associated both total cholesterol and LDL cholesterol to CV risk. Current studies have shown that there is discordance in quite a number of individuals based on the standard lipid profile. Thus, the determination of lipoprotein particle (LDL-P) numbers offers a more accurate risk assessment especially in those individuals with other comorbid conditions. A simple determination of total cholesterol with its subgroups HDL and LDL is thus no longer sufficient. As a consequence it is recommended to consult further parameters providing data beyond the conventional lipid panel.
2. Sachdeva, A., et al., Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am Heart J, 2009. 157(1): 111-117 e2.
numares offers clinical laboratories an on-site technology solution for cardiovascular risk assessment, i.e. an in-depth lipoprotein analysis to provide accurate diagnostic data for clinical decision making to physicians and health care professionals.
Compared to the standard lipid profile, the AXINON®lipoFIT®* test system is an advanced lipoprotein analysis providing a detailed and standardized examination of lipoprotein subclasses via Magnetic Group Signaling (MGS®) technology. For the first time, our CE-marked test allows measurement of lipoprotein concentration, size and distribution and also determines the quantity of the key lipids triglycerides, cholesterol and phospholipids in blood.
More information on the AXINON® lipoFIT® test system
The AXINON®lipoFIT® test system enables comprehensive lipoprotein analysis and is suited for solid high-throughput operation with minimal hands-on time.
The combination of MGS® and the AXINON® IVD System allows test-specific spectral analysis with highly-reproducible results. The system is easy to use with one-step sample preparation and ready-to-use reagents requiring minimal operator interaction. The test system is fast and efficient with automation capabilities allowing short hands-on-time and high walk-away capability.
numares licenses AXINON® Software, Magnetic Group Signaling (MGS®) technology and research methods/applications underlying our diagnostic products* to customers of the healthcare industry. For an individual licensing agreement, please get in contact with us.
To date, more than 2 million tests have been performed worldwide, using the numares’ technology.
There are several laboratories world-wide, offering advanced lipoprotein testing using numares technology.
Please find them here in alphabetical order:
* For Research Use only in the United States. numares’ products are not yet available for sale within the United States; they have not yet been approved or cleared by the U.S. Food and Drug Administration.